IBDEI3GW ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,58319,1,4,0)
 ;;=4^E11.321
 ;;^UTILITY(U,$J,358.3,58319,2)
 ;;=^5002634
 ;;^UTILITY(U,$J,358.3,58320,0)
 ;;=E11.329^^272^2906^67
 ;;^UTILITY(U,$J,358.3,58320,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58320,1,3,0)
 ;;=3^Type 2 DM w/ Mild Nonprolif DM Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,58320,1,4,0)
 ;;=4^E11.329
 ;;^UTILITY(U,$J,358.3,58320,2)
 ;;=^5002635
 ;;^UTILITY(U,$J,358.3,58321,0)
 ;;=E11.331^^272^2906^68
 ;;^UTILITY(U,$J,358.3,58321,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58321,1,3,0)
 ;;=3^Type 2 DM w/ Mod Nonprolif DM Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,58321,1,4,0)
 ;;=4^E11.331
 ;;^UTILITY(U,$J,358.3,58321,2)
 ;;=^5002636
 ;;^UTILITY(U,$J,358.3,58322,0)
 ;;=E11.339^^272^2906^69
 ;;^UTILITY(U,$J,358.3,58322,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58322,1,3,0)
 ;;=3^Type 2 DM w/ Mod Nonprolif DM Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,58322,1,4,0)
 ;;=4^E11.339
 ;;^UTILITY(U,$J,358.3,58322,2)
 ;;=^5002637
 ;;^UTILITY(U,$J,358.3,58323,0)
 ;;=E11.351^^272^2906^70
 ;;^UTILITY(U,$J,358.3,58323,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58323,1,3,0)
 ;;=3^Type 2 DM w/ Prolif DM Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,58323,1,4,0)
 ;;=4^E11.351
 ;;^UTILITY(U,$J,358.3,58323,2)
 ;;=^5002640
 ;;^UTILITY(U,$J,358.3,58324,0)
 ;;=E11.359^^272^2906^71
 ;;^UTILITY(U,$J,358.3,58324,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58324,1,3,0)
 ;;=3^Type 2 DM w/ Prolif DM Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,58324,1,4,0)
 ;;=4^E11.359
 ;;^UTILITY(U,$J,358.3,58324,2)
 ;;=^5002641
 ;;^UTILITY(U,$J,358.3,58325,0)
 ;;=E11.341^^272^2906^72
 ;;^UTILITY(U,$J,358.3,58325,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58325,1,3,0)
 ;;=3^Type 2 DM w/ Severe Nonprolif DM Retinopathy w/ Macular Edema
 ;;^UTILITY(U,$J,358.3,58325,1,4,0)
 ;;=4^E11.341
 ;;^UTILITY(U,$J,358.3,58325,2)
 ;;=^5002638
 ;;^UTILITY(U,$J,358.3,58326,0)
 ;;=E11.349^^272^2906^73
 ;;^UTILITY(U,$J,358.3,58326,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58326,1,3,0)
 ;;=3^Type 2 DM w/ Severe Nonprolif DM Retinopathy w/o Macular Edema
 ;;^UTILITY(U,$J,358.3,58326,1,4,0)
 ;;=4^E11.349
 ;;^UTILITY(U,$J,358.3,58326,2)
 ;;=^5002639
 ;;^UTILITY(U,$J,358.3,58327,0)
 ;;=E11.9^^272^2906^74
 ;;^UTILITY(U,$J,358.3,58327,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58327,1,3,0)
 ;;=3^Type 2 DM w/o Complications
 ;;^UTILITY(U,$J,358.3,58327,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,58327,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,58328,0)
 ;;=H35.363^^272^2906^18
 ;;^UTILITY(U,$J,358.3,58328,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58328,1,3,0)
 ;;=3^Drusen of Macular,Bilateral
 ;;^UTILITY(U,$J,358.3,58328,1,4,0)
 ;;=4^H35.363
 ;;^UTILITY(U,$J,358.3,58328,2)
 ;;=^5005660
 ;;^UTILITY(U,$J,358.3,58329,0)
 ;;=H35.362^^272^2906^19
 ;;^UTILITY(U,$J,358.3,58329,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58329,1,3,0)
 ;;=3^Drusen of Macular,Left Eye
 ;;^UTILITY(U,$J,358.3,58329,1,4,0)
 ;;=4^H35.362
 ;;^UTILITY(U,$J,358.3,58329,2)
 ;;=^5005659
 ;;^UTILITY(U,$J,358.3,58330,0)
 ;;=H35.361^^272^2906^20
 ;;^UTILITY(U,$J,358.3,58330,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58330,1,3,0)
 ;;=3^Drusen of Macular,Right Eye
 ;;^UTILITY(U,$J,358.3,58330,1,4,0)
 ;;=4^H35.361
 ;;^UTILITY(U,$J,358.3,58330,2)
 ;;=^5005658
 ;;^UTILITY(U,$J,358.3,58331,0)
 ;;=H04.123^^272^2906^21
 ;;^UTILITY(U,$J,358.3,58331,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,58331,1,3,0)
 ;;=3^Dry Eye Syndrome,Bilateral Lacrimal Glands
 ;;^UTILITY(U,$J,358.3,58331,1,4,0)
 ;;=4^H04.123
